154 related articles for article (PubMed ID: 38455491)
1. Serum NY-ESO-1 and p53 antibodies as useful tumor markers in gastric cancer.
Kawada J; Saito T; Kurokawa Y; Kawabata R; Takeno A; Takeoka T; Nose Y; Wada H; Eguchi H; Doki Y;
Ann Gastroenterol Surg; 2024 Mar; 8(2):243-250. PubMed ID: 38455491
[TBL] [Abstract][Full Text] [Related]
2. Serum NY-ESO-1 antibody as a predictive biomarker for postoperative recurrence of gastric cancer: a multicenter prospective observational study.
Saito T; Kurokawa Y; Fujitani K; Kawabata R; Takeno A; Mikami J; Endo S; Matsuyama J; Akamaru Y; Hirota M; Kishi K; Urakawa S; Yamamoto K; Tanaka K; Takahashi T; Oka M; Wada H; Eguchi H; Doki Y
Br J Cancer; 2024 Apr; 130(7):1157-1165. PubMed ID: 38326601
[TBL] [Abstract][Full Text] [Related]
3. NY-ESO-1 antibody as a novel tumour marker of gastric cancer.
Fujiwara S; Wada H; Kawada J; Kawabata R; Takahashi T; Fujita J; Hirao T; Shibata K; Makari Y; Iijima S; Nishikawa H; Jungbluth AA; Nakamura Y; Kurokawa Y; Yamasaki M; Miyata H; Nakajima K; Takiguchi S; Nakayama E; Mori M; Doki Y
Br J Cancer; 2013 Mar; 108(5):1119-25. PubMed ID: 23403818
[TBL] [Abstract][Full Text] [Related]
4. Prognostic impact of p53 and/or NY-ESO-1 autoantibody induction in patients with gastroenterological cancers.
Hoshino I; Nabeya Y; Takiguchi N; Gunji H; Ishige F; Iwatate Y; Shiratori F; Yajima S; Okada R; Shimada H
Ann Gastroenterol Surg; 2020 May; 4(3):275-282. PubMed ID: 32490341
[TBL] [Abstract][Full Text] [Related]
5. NY-ESO-1 autoantibody as a tumor-specific biomarker for esophageal cancer: screening in 1969 patients with various cancers.
Oshima Y; Shimada H; Yajima S; Nanami T; Matsushita K; Nomura F; Kainuma O; Takiguchi N; Soda H; Ueda T; Iizasa T; Yamamoto N; Yamamoto H; Nagata M; Yokoi S; Tagawa M; Ohtsuka S; Kuwajima A; Murakami A; Kaneko H
J Gastroenterol; 2016 Jan; 51(1):30-4. PubMed ID: 25906289
[TBL] [Abstract][Full Text] [Related]
6. The role of serum and gastric juice levels of carcinoembryonic antigen, CA19.9 and CA72.4 in patients with gastric cancer.
Tocchi A; Costa G; Lepre L; Liotta G; Mazzoni G; Cianetti A; Vannini P
J Cancer Res Clin Oncol; 1998; 124(8):450-5. PubMed ID: 9750022
[TBL] [Abstract][Full Text] [Related]
7. Changing pattern of tumor markers in recurrent colorectal cancer patients before surgery to recurrence: serum p53 antibodies, CA19-9 and CEA.
Ushigome M; Shimada H; Miura Y; Yoshida K; Kaneko T; Koda T; Nagashima Y; Suzuki T; Kagami S; Funahashi K
Int J Clin Oncol; 2020 Apr; 25(4):622-632. PubMed ID: 31820210
[TBL] [Abstract][Full Text] [Related]
8. The utility of tumor marker combination, including serum P53 antibody, in colorectal cancer treatment.
Tokunaga R; Sakamoto Y; Nakagawa S; Yoshida N; Baba H
Surg Today; 2017 May; 47(5):636-642. PubMed ID: 28062920
[TBL] [Abstract][Full Text] [Related]
9. Anti-NY-ESO-1 autoantibody may be a tumor marker for intrahepatic cholangiocarcinoma.
Zhang Z; Li FF; Lu MD; Zhang SX; Li YX
Oncotarget; 2017 Nov; 8(61):103283-103289. PubMed ID: 29262561
[TBL] [Abstract][Full Text] [Related]
10. Clinicopathological assessment of cancer/testis antigens NY‑ESO‑1 and MAGE‑A4 in osteosarcoma.
Hashimoto K; Nishimura S; Ito T; Oka N; Kakinoki R; Akagi M
Eur J Histochem; 2022 Jun; 66(3):. PubMed ID: 35736245
[TBL] [Abstract][Full Text] [Related]
11. Expression and immunogenicity of NY-ESO-1 in colorectal cancer.
Li Y; Song R; Li X; Xu F
Exp Ther Med; 2017 Jun; 13(6):3581-3585. PubMed ID: 28588683
[TBL] [Abstract][Full Text] [Related]
12. Comparison of CEA and CA19-9 as a predictive factor for recurrence after curative gastrectomy in gastric cancer.
Shibata C; Nakano T; Yasumoto A; Mitamura A; Sawada K; Ogawa H; Miura T; Ise I; Takami K; Yamamoto K; Katayose Y
BMC Surg; 2022 Jun; 22(1):213. PubMed ID: 35655198
[TBL] [Abstract][Full Text] [Related]
13. Diagnostic and prognostic values of anti-helicobacter pylori antibody combined with serum CA724, CA19-9, and CEA for young patients with early gastric cancer.
Gong X; Zhang H
J Clin Lab Anal; 2020 Jul; 34(7):e23268. PubMed ID: 32118318
[TBL] [Abstract][Full Text] [Related]
14. Cancer/testis antigen expression and autologous humoral immunity to NY-ESO-1 in gastric cancer.
Wang Y; Wu XJ; Zhao AL; Yuan YH; Chen YT; Jungbluth AA; Gnjatic S; Santiago D; Ritter G; Chen WF; Old LJ; Ji JF
Cancer Immun; 2004 Nov; 4():11. PubMed ID: 15516106
[TBL] [Abstract][Full Text] [Related]
15. Dose-dependent effects of NY-ESO-1 protein vaccine complexed with cholesteryl pullulan (CHP-NY-ESO-1) on immune responses and survival benefits of esophageal cancer patients.
Kageyama S; Wada H; Muro K; Niwa Y; Ueda S; Miyata H; Takiguchi S; Sugino SH; Miyahara Y; Ikeda H; Imai N; Sato E; Yamada T; Osako M; Ohnishi M; Harada N; Hishida T; Doki Y; Shiku H
J Transl Med; 2013 Oct; 11():246. PubMed ID: 24093426
[TBL] [Abstract][Full Text] [Related]
16. Urine antibody against human cancer antigen NY-ESO-1.
Jäger D; Stockert E; Karbach J; Herrlinger K; Atmaca A; Arand M; Chen YT; Gnjatic S; Old LJ; Knuth A; Jäger E
Cancer Immun; 2002 Aug; 2():10. PubMed ID: 12747755
[TBL] [Abstract][Full Text] [Related]
17. Antigen-specific immunity in neuroblastoma patients: antibody and T-cell recognition of NY-ESO-1 tumor antigen.
Rodolfo M; Luksch R; Stockert E; Chen YT; Collini P; Ranzani T; Lombardo C; Dalerba P; Rivoltini L; Arienti F; Fossati-Bellani F; Old LJ; Parmiani G; Castelli C
Cancer Res; 2003 Oct; 63(20):6948-55. PubMed ID: 14583496
[TBL] [Abstract][Full Text] [Related]
18. Humoral immune responses of cancer patients against "Cancer-Testis" antigen NY-ESO-1: correlation with clinical events.
Jäger E; Stockert E; Zidianakis Z; Chen YT; Karbach J; Jäger D; Arand M; Ritter G; Old LJ; Knuth A
Int J Cancer; 1999 Oct; 84(5):506-10. PubMed ID: 10502728
[TBL] [Abstract][Full Text] [Related]
19. Persistent anti-NY-ESO-1-specific T cells and expression of differential biomarkers in a patient with metastatic gastric cancer benefiting from combined radioimmunotherapy treatment: a case report.
Merhi M; Raza A; Inchakalody VP; Siveen KS; Kumar D; Sahir F; Mestiri S; Hydrose S; Allahverdi N; Jalis M; Relecom A; Al Zaidan L; Hamid MSE; Mostafa M; Gul ARZ; Uddin S; Al Homsi M; Dermime S
J Immunother Cancer; 2020 Sep; 8(2):. PubMed ID: 32913031
[TBL] [Abstract][Full Text] [Related]
20. Human CLEC9A antibodies deliver NY-ESO-1 antigen to CD141
Masterman KA; Haigh OL; Tullett KM; Leal-Rojas IM; Walpole C; Pearson FE; Cebon J; Schmidt C; O'Brien L; Rosendahl N; Daraj G; Caminschi I; Gschweng EH; Hollis RP; Kohn DB; Lahoud MH; Radford KJ
J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32737142
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
